Valuation: Resverlogix Corp.

Market Cap 2.6Cr 1.87Cr 1.62Cr 1.52Cr 1.39Cr 178.88Cr 2.65Cr 18Cr 6.97Cr 90Cr 7.04Cr 6.89Cr 298.71Cr P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 11Cr 8.05Cr 6.97Cr 6.55Cr 5.96Cr 768.76Cr 11Cr 77Cr 30Cr 385.97Cr 30Cr 30Cr 1.28TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 week+10.53%
Current month+10.53%
1 month+5.00%
3 months+10.53%
6 months+10.53%
Current year+5.00%
1 week 0.1
Extreme 0.095
0.11
1 month 0.09
Extreme 0.09
0.12
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Option

Chief Financial Officer

3,50,000 0.1018%
06/07/26 Option

Chief Financial Officer

-3,50,000 0.1018%
06/07/26 Option

Chief Executive Officer

5,00,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+10.53%-4.55%+5.00% 2.6Cr
-1.90%+2.85%+62.82%+104.13% 7.01TCr
-3.21%-4.32%+31.85%+57.27% 5.29TCr
-2.05%-5.61%-3.18%+449.71% 2.7TCr
-1.27%-1.57%+45.90%+8.25% 2.36TCr
+1.05%-0.62%-18.00%-11.93% 2.34TCr
+3.81%+20.97%+266.37%+531.28% 1.94TCr
+0.10%+1.40%+35.36%-19.94% 1.87TCr
-0.95%-3.52%+19.93%+594.00% 1.59TCr
+1.24%-5.23%+33.75%+137.66% 1.27TCr
Average -0.32%+2.80%+47.03%+185.54% 2.64TCr
Weighted average by Cap. -1.09%+0.56%+50.23%+164.98%

Financials

2024 2025
Net sales - -
Net income -76.35L -54.99L -47.58L -44.74L -40.68L -52Cr -77.69L -5.24Cr -2.05Cr -26Cr -2.07Cr -2.02Cr -88Cr -77.67L -55.95L -48.41L -45.51L -41.38L -53Cr -79.03L -5.33Cr -2.08Cr -27Cr -2.1Cr -2.06Cr -89Cr
Net Debt 8.19Cr 5.9Cr 5.1Cr 4.8Cr 4.36Cr 562.93Cr 8.33Cr 56Cr 22Cr 282.63Cr 22Cr 22Cr 940.03Cr 8.58Cr 6.18Cr 5.35Cr 5.03Cr 4.57Cr 589.87Cr 8.73Cr 59Cr 23Cr 296.16Cr 23Cr 23Cr 985.02Cr
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
14/26/14 CA$0.1050 0.00% 7,541
13/26/13 CA$0.1050 +5.00% 65,000
12/26/12 CA$0.1000 0.00% 1,084
11/26/11 CA$0.1000 0.00% 2,950
10/26/10 CA$0.1000 +5.26% 27,000